Welcome to the IMI EoI submission tool!
The IMI electronic submission tool is to be used for submitting an Expression of Interest (EoI) in response to a topic from the 1st IMI Call; no other means of submission will be accepted. It is possible to update EoIs until the call deadline, however, please note that only the most recent version will be considered.
REMINDER!
EFPIA Companies can not be part of a submitted Expression of Interest. Industry participation is organised by EFPIA at the next stage in the Call process
| Call ID |
IMI_Call_2008_1 |
| Status |
Closed |
| Opening of period for submitting EoIs |
1 June 2008 |
| Deadline |
15 July 2008 at 17:00:00 (Brussels local time) |
All documents related to the IMI 1st Call are available at imi.europa.eu.
If you have any question related to the Call, please use our Helpdesk form.
| Call Topic Codes |
Call Topic Titles |
| IMI_Call_2008_1_01 |
Improve Predictivity and Minimization Strategies of Immunogenicity for Biotherapeutics in Man |
| IMI_Call_2008_1_02 |
Non-genotoxic carcinogenesis: Identification of early markers and molecular classification of tumours |
| IMI_Call_2008_1_03 |
Development of expert (QSAR) systems for in silico toxicity prediction |
| IMI_Call_2008_1_04 |
Improved Predictivity of Non-Clinical Safety Evaluation |
| IMI_Call_2008_1_05 |
Qualification of Translational Safety Biomarkers from Non Clinical to Early Clinical Studies |
| IMI_Call_2008_1_06 |
Improving and strengthening the monitoring of the benefit/risk of medicines marketed in the EU |
| IMI_Call_2008_1_07 |
Islet cell research: Improving b-cell function and identification of diagnostic biomarkers for treatment monitoring in diabetes |
| IMI_Call_2008_1_08 |
Surrogate markers for micro- and macrovascular hard endpoints to shorten clinical trials on diabetes |
| IMI_Call_2008_1_09 |
Pain research: Innovative preclinical and clinical rapprochement to produce biomarkers for safer and more effective treatments. |
| IMI_Call_2008_1_10 |
New tools for the development of novel therapies in psychiatric disorders |
| IMI_Call_2008_1_11 |
Neurodegenerative disorders : Bridging the preclinical-clinical divide |
| IMI_Call_2008_1_12 |
Understanding Severe Asthma, the fundamental bottleneck to advancing new medicines for the syndrome |
| IMI_Call_2008_1_13 |
COPD Patient Reported Outcomes (PROs), a major bottleneck to understanding patient and economic benefits of new therapies. |
| IMI_Call_2008_1_14 |
Establishment of a network to facilitate and coordinate European training and education relevant for stakeholders of medicines research and development |
| IMI_Call_2008_1_15 |
IMI Safety Sciences for Medicines Training Programme |
| IMI_Call_2008_1_16 |
IMI Pharmaceutical Medicine Training Programme |
| IMI_Call_2008_1_17 |
IMI Integrated Medicines Development Course Programme for non-specialists |
| IMI_Call_2008_1_18 |
IMI Pharmacovigilance Training Programme |